<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355742</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10235</org_study_id>
    <nct_id>NCT03355742</nct_id>
  </id_info>
  <brief_title>XIENCE 28 Global Study</brief_title>
  <official_title>XIENCE 28 Global Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized&#xD;
      trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet&#xD;
      therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary&#xD;
      intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting&#xD;
      Coronary Stent System [EECSS], XIENCE Alpine EECSS, XIENCE PROX EECSS, XIENCE ProA EECSS or&#xD;
      XIENCE Sierra EECSS of coronary drug-eluting stents&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The XIENCE 28 Global Study will evaluate the safety of 1-month DAPT following XIENCE&#xD;
      implantation in HBR patients. A minimum of 800 to a maximum of 960 subjects will be&#xD;
      registered from approximately 50 sites globally and subject registration is capped at 120 per&#xD;
      site. Eligibility of P2Y12 receptor inhibitor discontinuation will be assessed at 1-month&#xD;
      follow-up. Subjects who are free from myocardial infarction (MI), repeat coronary&#xD;
      revascularization, stroke, or stent thrombosis (ARC definite/probable) within 1 month (prior&#xD;
      to 1-month visit but at least 28 days) after stenting and have been compliant with 1-month&#xD;
      DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for &gt; 7&#xD;
      consecutive days are considered as &quot;1-month clear&quot;, and will discontinue P2Y12 receptor&#xD;
      inhibitor as early as 28 days and continue with aspirin monotherapy through 12-month&#xD;
      follow-up.&#xD;
&#xD;
      All registered subjects will be followed at 1, 3, 6 and 12 months post index procedure. The&#xD;
      data collected from the XIENCE 28 Global Study will be compared with the historical control&#xD;
      of non-complex HBR subjects treated with standard DAPT up to 12 months from the XIENCE V USA&#xD;
      Study .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE), by Propensity Score Quintiles</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of All Death or All MI (Modified ARC)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of All Death or All MI (Modified ARC)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of All Death or All MI (Modified ARC)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Defined by the Bleeding Academic Research Consortium (BARC) Type 2-5 and Type 3-5</measure>
    <time_frame>From 1 to 6 months</time_frame>
    <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Defined by the BARC, Type 2-5 and Type 3-5</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Defined by BARC, Type 2-5 and Type 3-5</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">963</enrollment>
  <condition>Bleeding Disorder</condition>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke Hemorrhagic</condition>
  <condition>Hematological Disease</condition>
  <condition>Thrombocytopenia</condition>
  <condition>Coagulation Disorder</condition>
  <condition>Anemia</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>XIENCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XIENCE + Short duration (1 month) of DAPT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE</intervention_name>
    <description>Subjects who received XIENCE family stent systems will be included.</description>
    <arm_group_label>XIENCE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPT</intervention_name>
    <description>1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
    <arm_group_label>XIENCE</arm_group_label>
    <other_name>Dual antiplatelet therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is considered at HBR, defined as meeting one or more of the following criteria&#xD;
             at the time of registration and in the opinion of the referring physician, the risk of&#xD;
             major bleeding with &gt; 1-month DAPT outweighs the benefit:&#xD;
&#xD;
               1. Subjects ≥ 75 years of age.&#xD;
&#xD;
               2. Clinical indication for chronic (at least 6 months) or lifelong anticoagulation&#xD;
                  therapy.&#xD;
&#xD;
               3. History of major bleeding which required medical attention within 12 months of&#xD;
                  the index procedure.&#xD;
&#xD;
               4. History of stroke (ischemic or hemorrhagic).&#xD;
&#xD;
               5. Renal insufficiency (creatinine ≥ 2.0 mg/dl) or failure (dialysis dependent).&#xD;
&#xD;
               6. Systemic conditions associated with an increased bleeding risk (e.g.&#xD;
                  hematological disorders, including a history of or current thrombocytopenia&#xD;
                  defined as a platelet count &lt;100,000/mm^3, or any known coagulation disorder&#xD;
                  associated with increased bleeding risk).&#xD;
&#xD;
               7. Anemia with hemoglobin &lt; 11g/dl.&#xD;
&#xD;
          2. Subject must be at least 18 years of age.&#xD;
&#xD;
          3. Subject must provide written informed consent as approved by the Ethics Committee (EC)&#xD;
             of the respective clinical site prior to any trial related procedure.&#xD;
&#xD;
          4. Subject is willing to comply with all protocol requirements, including agreement to&#xD;
             stop taking P2Y12 inhibitor at 1 month, if eligible per protocol.&#xD;
&#xD;
          5. Subject must agree not to participate in any other clinical trial for a period of one&#xD;
             year following the index procedure.&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          1. Up to three target lesions with a maximum of two target lesions per epicardial vessel.&#xD;
&#xD;
             Note:&#xD;
&#xD;
               1. The definition of epicardial vessels means left anterior descending coronary&#xD;
                  artery (LAD), left circumflex coronary artery (LCX) and right coronary artery&#xD;
                  (RCA) and their branches. For example, the subject must not have &gt;2 lesions&#xD;
                  requiring treatment within both the LAD and a diagonal branch in total.&#xD;
&#xD;
               2. If there are two target lesions within the same epicardial vessel, the two target&#xD;
                  lesions must be at least 15 mm apart per visual estimation; otherwise this is&#xD;
                  considered as a single target lesion.&#xD;
&#xD;
          2. Target lesion must be located in a native coronary artery with visually estimated&#xD;
             reference vessel diameter between 2.25 mm and 4.25 mm.&#xD;
&#xD;
          3. Exclusive use of XIENCE family of stent systems during the index procedure.&#xD;
&#xD;
          4. Target lesion has been treated successfully, which is defined as achievement of a&#xD;
             final in-stent residual diameter stenosis of &lt;20% with final thrombolysis in&#xD;
             myocardial infarction (TIMI-3) flow assessed by online quantitative angiography or&#xD;
             visual estimation, with no residual dissection National Heart, Lung, and Blood&#xD;
             Institute (NHLBI) grade ≥ type B, and no transient or sustained angiographic&#xD;
             complications (e.g., distal embolization, side branch closure), no chest pain lasting&#xD;
             &gt; 5 minutes, and no ST segment elevation &gt; 0.5mm or depression lasting &gt; 5 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with an indication for the index procedure of acute ST-segment elevation MI&#xD;
             (STEMI).&#xD;
&#xD;
          2. Subject has a known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, P2Y12 inhibitors (clopidogrel/prasugrel/ticagrelor), everolimus,&#xD;
             cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast&#xD;
             sensitivity that cannot be adequately pre-medicated.&#xD;
&#xD;
          3. Subject with implantation of another drug-eluting stent (other than XIENCE) within 12&#xD;
             months prior to index procedure.&#xD;
&#xD;
          4. Subject has a known left ventricular ejection fraction (LVEF) &lt;30%.&#xD;
&#xD;
          5. Subject judged by physician as inappropriate for discontinuation from P2Y12 inhibitor&#xD;
             use at 1 month, due to another condition requiring chronic P2Y12 inhibitor use.&#xD;
&#xD;
          6. Subject with planned surgery or procedure necessitating discontinuation of P2Y12&#xD;
             inhibitor within 1 month following index procedure.&#xD;
&#xD;
          7. Subject with a current medical condition with a life expectancy of less than 12&#xD;
             months.&#xD;
&#xD;
          8. Subject intends to participate in an investigational drug or device trial within 12&#xD;
             months following the index procedure.&#xD;
&#xD;
          9. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to the index procedure per site&#xD;
             standard test.&#xD;
&#xD;
             Note: Female subjects of childbearing potential should be instructed to use safe&#xD;
             contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive&#xD;
             pills, implants, transdermal patches hormonal vaginal devices, injections with&#xD;
             prolonged release). It is accepted, in certain cases, to include subjects having a&#xD;
             sterilised regular partner or subjects using a double barrier contraceptive method.&#xD;
             However, this should be explicitly justified in special circumstances arising from the&#xD;
             trial design, product characteristics and/or trial population.&#xD;
&#xD;
         10. Presence of other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, could limit the&#xD;
             subject's ability to participate in the clinical investigation or to comply with&#xD;
             follow-up requirements, or impact the scientific soundness of the clinical&#xD;
             investigation results.&#xD;
&#xD;
         11. Subject is currently participating in another clinical trial that has not yet&#xD;
             completed its primary endpoint.&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          1. Target lesion is in a left main location.&#xD;
&#xD;
          2. Target lesion is located within an arterial or saphenous vein graft.&#xD;
&#xD;
          3. Target lesion is restenotic from a previous stent implantation.&#xD;
&#xD;
          4. Target lesion is a chronic total occlusion (CTO, defined as lesion with TIMI flow 0&#xD;
             for at least 3 months).&#xD;
&#xD;
          5. Target lesion is implanted with overlapping stents, whether planned or for bailout.&#xD;
&#xD;
        Note: If there is more than one target lesion, all target lesions must satisfy the&#xD;
        angiographic eligibility criteria. Non-target lesion (i.e., lesions that do not meet the&#xD;
        angiographic criteria listed above) treatments are not allowed during the index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum GmbH</name>
      <address>
        <city>Linz</city>
        <state>Upr Aus</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Campus Aalst</name>
      <address>
        <city>Aalst</city>
        <state>Eflndrs</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Flemish</state>
        <zip>42100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing AnZhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>N China</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Bad-wur</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen GmbH</name>
      <address>
        <city>Essen</city>
        <state>N. Rhin</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITATSMEDIZIN der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhinela</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>4289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schlesw</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Campus Benjamin Franklin (CBF)</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKE Hamburg (Universitatsklinik Eppendorf)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Ko</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Ko</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong (Queen Mary Hospital)</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Ko</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mediterranea</name>
      <address>
        <city>Napoli</city>
        <state>Campani</state>
        <zip>80122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Federico II - Università degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <state>Campani</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az.Osp. Universitaria di Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Emi-rom</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU di Parma</name>
      <address>
        <city>Parma</city>
        <state>Emi-rom</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Latium</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>Latium</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Lombard</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheperziekenhuis</name>
      <address>
        <city>Emmen</city>
        <state>Drenthe</state>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesld</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid</state>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <state>Lisbon</state>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Maria Hospital</name>
      <address>
        <city>Lisboa</city>
        <state>Lisbon</state>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <state>Central</state>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <state>Central</state>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCU Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalu</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabr</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Catalon</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalon</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <state>Cstleon</state>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro Dept of Interventional Cardiology</name>
      <address>
        <city>Vigo</city>
        <state>Pontev</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Basel</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>LinKou</city>
        <state>Ntaiwan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (VGH)</name>
      <address>
        <city>Taipei City</city>
        <state>Ntaiwan</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Ntaiwan</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Staiwan</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>NE Engl</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craigavon Area Hospital</name>
      <address>
        <city>Portadown</city>
        <state>Nirelnd</state>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Soeast</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Sowest</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Sowest</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <results_first_submitted>October 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XIENCE</keyword>
  <keyword>High bleeding risk (HBR)</keyword>
  <keyword>Dual antiplatelet therapy (DAPT)</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Drug eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03355742/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03355742/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 963 subjects were enrolled across 52 sites globally, between 09 February, 2018 and 30 April, 2020. The last subject last visit was on 30 April, 2020 and the final data was extracted from the database on 01 July, 2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE</title>
          <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="963"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="864"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Closure of the Study, Other Status Change Reason, Missed Visit, Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XIENCE</title>
          <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="963"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.84" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Percutaneous Coronary Intervention (PCI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="963"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Major Bleeding</title>
          <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="961"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE), by Propensity Score Quintiles</title>
        <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE), by Propensity Score Quintiles</title>
          <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</title>
        <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</title>
          <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</title>
        <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Net Adverse Clinical Endpoint (NACE)</title>
          <description>Net Adverse Clinical Endpoint (NACE):&#xD;
A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
        <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
          <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="816"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
        <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
          <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="791"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
        <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis (ARC Definite/Probable, ARC Definite)</title>
          <description>Definite stent thrombosis:&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.&#xD;
Probable stent thrombosis:&#xD;
Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:&#xD;
Any unexplained death within the first 30 days&#xD;
Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up, or withdrew consent, or died before time point analyzed, without any Stent Thrombosis event, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death, Cardiac Death, Vascular Death, Non-cardiovascular Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
        <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
          <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
        <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
          <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
        <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI) and MI Attributed to Target Vessel (TV-MI, Modified ARC)</title>
          <description>Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
        <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
          <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
        <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
          <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
        <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Cardiac Death or MI (Modified ARC)</title>
          <description>Cardiac death:&#xD;
Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI:&#xD;
Within 48h after PCI: CK-MB &gt;3 x URL or Troponin &gt; 3 x URL with baseline value &lt; URL&#xD;
Within 72h after CABG: CK-MB &gt;5 x URL or Troponin &gt; 5 x URL with baseline value &lt; URL&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
        <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
          <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
        <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
          <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
        <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of All Death or All MI (Modified ARC)</title>
          <description>All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.&#xD;
MI (Modified ARC):&#xD;
Patients present any of the following clinical or imaging evidence of ischemia:&#xD;
Clinical symptoms of ischemia;&#xD;
ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;&#xD;
Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)&#xD;
AND confirmed with elevated cardiac biomarkers per ARC criteria:&#xD;
Periprocedural MI&#xD;
Spontaneous MI (&gt; 48h following PCI, &gt; 72h following CABG): CK-MB &gt; URL or Troponin &gt; URL with baseline value &lt; URL</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
        <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
          <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="815"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
        <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
          <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
        <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Stroke, Ischemic Stroke and Hemorrhagic Stroke</title>
          <description>An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.&#xD;
Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.&#xD;
Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.&#xD;
Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.&#xD;
Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Lesion Revascularization (CI-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.&#xD;
A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-indicated Target Vessel Revascularization (CI-TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself&#xD;
A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:&#xD;
A positive history of recurrent angina pectoris, presumably related to the target vessel;&#xD;
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;&#xD;
Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);&#xD;
A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
        <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
          <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
        <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
          <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
        <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF, Composite of Cardiac Death, TV-MI and CI-TLR)</title>
          <description>TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
        <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
          <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
        <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
          <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
        <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure (TVF, a Composite of Cardiac Death, TV-MI and CI-TVR)</title>
          <description>TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Defined by the Bleeding Academic Research Consortium (BARC) Type 2-5 and Type 3-5</title>
        <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
        <time_frame>From 1 to 6 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Defined by the Bleeding Academic Research Consortium (BARC) Type 2-5 and Type 3-5</title>
          <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BARC Type 2-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC Type 3-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Defined by the BARC, Type 2-5 and Type 3-5</title>
        <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
        <time_frame>From 6 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Defined by the BARC, Type 2-5 and Type 3-5</title>
          <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BARC Type 2-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC Type 3-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Defined by BARC, Type 2-5 and Type 3-5</title>
        <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
        <time_frame>From 1 to 12 months</time_frame>
        <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE</title>
            <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Defined by BARC, Type 2-5 and Type 3-5</title>
          <description>Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5&#xD;
Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding.</description>
          <population>The number of participants analyzed includes subjects who completed follow up at the given time point. Subjects who were lost to follow-up or withdrew consent prior to that time point, without the endpoint of interest, are excluded from the denominator.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="792"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BARC Type 2-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC Type 3-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE</title>
          <description>XIENCE + Short duration (1 month) of DAPT&#xD;
XIENCE: Subjects who received XIENCE family stent systems will be included.&#xD;
DAPT: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="374" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nephrogenic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Normochromic Normocytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bifascicular Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Congestive Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dressler's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myopericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sinoatrial Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Faeces Discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peritoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cholecystitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haematoma Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Infectious Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Muscle Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vulval Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cranial Nerve Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram Coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Blood Pressure Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Systemic Lupus Erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Lymphocytic Leukaemia Re</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Biliary Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carc</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Tract Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pleural Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urethral Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cauda Equina Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Complex Regional Pain Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Neurodegenerative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Fistula Operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Pacemaker Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Colon Polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hip Arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Limb Immobilisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vascular Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="357" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Microcytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Normochromic Normocytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Spontaneous Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrial Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block First Degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Coronary Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Epigastric Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastric Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tooth Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pacemaker Generated Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tinea Cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac Procedure Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Calcium Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Blood Glucose Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Blood Thyroid Stimulating Hormone Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cardiac Enzymes Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Glycosylated Haemoglobin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prostatic Specific Antigen Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Troponin I Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Muscle Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Systemic Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Oesophageal Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cervicogenic Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Petit Mal Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Tunnel Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vaginismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Rash Generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vascular Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>Vascular Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Siok Hwee Tan, PhD, Principal Clinical Research Scientist</name_or_title>
      <organization>Clinical Affairs, Abbott Vascular</organization>
      <phone>+1 408-845-3581</phone>
      <email>siokhwee.tan@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

